OTCMKTS:ELTP Elite Pharmaceuticals (ELTP) Stock Price, News & Analysis $0.36 -0.01 (-2.49%) As of 03:23 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Elite Pharmaceuticals Stock (OTCMKTS:ELTP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Elite Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.35▼$0.3850-Day Range$0.33▼$0.4452-Week Range$0.33▼$0.80Volume325,883 shsAverage Volume636,775 shsMarket Capitalization$387.55 millionP/E Ratio12.00Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Elite Pharmaceuticals, Inc. is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care. Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities. The company collaborates with contract manufacturing organizations and leverages distribution networks to supply products to wholesalers, hospitals and healthcare providers across the United States. Through these alliances, Elite Pharmaceuticals aims to streamline supply chains and enhance product availability for its key markets. Specific information on the company’s leadership team and key historical milestones is limited in publicly available sources. Industry records indicate the management group brings experience in pharmaceutical sourcing, regulatory affairs and product development. Elite Pharmaceuticals continues to explore opportunities for organic growth, business development and potential acquisitions, positioning itself to capitalize on innovation within the specialty pharmaceutical sector.AI Generated. May Contain Errors. Read More Elite Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreELTP MarketRank™: Elite Pharmaceuticals scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Elite Pharmaceuticals. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Elite Pharmaceuticals is 12.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Elite Pharmaceuticals is 12.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.46.Price to Book Value per Share RatioElite Pharmaceuticals has a P/B Ratio of 7.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.28% of the float of Elite Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverElite Pharmaceuticals has a short interest ratio ("days to cover") of 3.24, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elite Pharmaceuticals has recently decreased by 0.87%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldElite Pharmaceuticals does not currently pay a dividend.Dividend GrowthElite Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Elite Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Elite Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Elite Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders14.42% of the stock of Elite Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions0.01% of the stock of Elite Pharmaceuticals is held by institutions.Read more about Elite Pharmaceuticals' insider trading history. Receive ELTP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elite Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELTP Stock News HeadlinesElite Pharmaceuticals (OTCMKTS:ELTP) Shares Pass Below 200 Day Moving Average - Should You Sell?June 18 at 4:01 AM | americanbankingnews.comElite Pharmaceuticals Inc (ELTP) Q3 2026 Earnings Call Highlights: Record Revenue Surge and ...February 24, 2026 | finance.yahoo.comStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.June 18 at 1:00 AM | Porter & Company (Ad)Elite Pharmaceuticals, Inc. (ELTP) Q3 2026 Earnings Call Prepared Remarks TranscriptFebruary 18, 2026 | seekingalpha.comElite Pharmaceuticals, Inc. (OTC:ELTP) Q2 2026 Earnings Call TranscriptNovember 18, 2025 | msn.comElite Pharmaceuticals Inc (ELTP) Q2 2026 Earnings Call Highlights: Surging Revenues and ...November 18, 2025 | finance.yahoo.comElite Pharmaceuticals, Inc. (ELTP) Q2 2026 Earnings Call TranscriptNovember 17, 2025 | seekingalpha.comElite Pharmaceuticals Receives FDA Approval for Generic Requip XL(R)November 12, 2025 | finance.yahoo.comSee More Headlines ELTP Stock Analysis - Frequently Asked Questions How have ELTP shares performed this year? Elite Pharmaceuticals' stock was trading at $0.4903 at the beginning of the year. Since then, ELTP stock has decreased by 26.6% and is now trading at $0.3598. How were Elite Pharmaceuticals' earnings last quarter? Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) announced its quarterly earnings results on Tuesday, February, 17th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter. The specialty pharmaceutical company earned $31.59 million during the quarter. Elite Pharmaceuticals had a trailing twelve-month return on equity of 47.93% and a net margin of 30.98%. Read the conference call transcript. How do I buy shares of Elite Pharmaceuticals? Shares of ELTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Elite Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Elite Pharmaceuticals investors own include Research Frontiers (REFR), Co-Diagnostics (CODX), Novavax (NVAX), FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO). Company Calendar Last Earnings2/17/2026Today6/18/2026Fiscal Year End3/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:ELTP CIK1053369 Webwww.elitepharma.com Phone(201) 750-2646Fax201-750-2755Employees40Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.03 Trailing P/E Ratio12.00 Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.32 million Net Margins30.98% Pretax Margin39.42% Return on Equity47.93% Return on Assets25.81% Debt Debt-to-Equity Ratio0.05 Current Ratio7.34 Quick Ratio5.44 Sales & Book Value Annual Sales$84.04 million Price / Sales4.61 Cash Flow$0.02 per share Price / Cash Flow21.50 Book Value$0.05 per share Price / Book7.20Miscellaneous Outstanding Shares1,077,140,000Free Float921,813,000Market Cap$387.55 million OptionableNot Optionable Beta0.38 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:ELTP) was last updated on 6/18/2026 by MarketBeat.com Staff. From Our PartnersAI Breakthrough Could Soon Reorder Stock Market Winners and LosersA powerful new form of AI has emerged from a Silicon Valley firm - and Marc Chaikin believes it could fundamen...Chaikin Analytics | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredSMX: From Under-the-Radar to Must-Watch!SMX (Security Matters) PLC is a small-cap building molecular-level tracking technology that embeds secure digi...Smallcaps Daily | SponsoredFree today: My 7-point options checklistBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elite Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elite Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
